The antitumor effect of
NC-190, N-beta-dimethylaminoethyl-9-carboxy-5-hydroxy-10-methoxybenzo [alpha] phenazine-6-carboxamide
sodium salt, with a new experimental mouse model was studied. Intratumoral administration of
NC-190 strongly inhibited the growth of Meth-A solid
tumors in male BALB/c mice and led to a complete
tumor regression and also resistance to the reinoculated
tumor. Subsequently, the anti-metastatic effect of
NC-190 was examined in the double grafted
tumor system, in which mice first received simultaneous intradermal inoculations of Meth-A in both right (10(6) cells) and left (2 X 10(5) cells) flanks and were then injected with 25 micrograms of
NC-190 in the right
tumor on days 3, 4 and 5.
NC-190 inhibited the growth of not only the right but also the left, non-treated
tumor. Immunized spleen cells were taken from mice which had been cured by the intratumoral administration of
NC-190. Adoptive transfer of
NC-190 immunized spleen cells caused a complete regression of Meth-A
tumors. The effector cell activity was lost only
after treatment with
anti-Lyt-2 antibody. These results suggest that intratumoral administration of
NC-190 might induce Lyt-2 positive cytotoxic cells in the spleen and the left, non-treated
tumor. In BALB/c nude mice,
NC-190 inhibited slightly the growth of the right
tumor but did not that of the left
tumor. Therefore, the antitumor activity of
NC-190 in the double grafted
tumor system was judged as associated with a sequential immune mechanism in which T cells may play an important role. TILs (tumor infiltrating lymphocytes) obtained from the left and right sides
tumors treated with
NC-190 were examined by Winn assay for their antitumor activity against Meth-A
sarcoma in BALB/c mice. TILs obtained from neither sides inhibited the growth of admixed Meth-A cells. Different from
immunopotentiators such PSK or
IL-1,
NC-190 enhanced neither concomitant immunity nor sinecomitant immunity.